Your browser doesn't support javascript.
loading
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS.
Zhang, Weina; Wang, Guihua; Xu, Zhi-Gang; Tu, Haiqing; Hu, Fuqing; Dai, Jiang; Chang, Yan; Chen, Yaqi; Lu, Yanjun; Zeng, Haolong; Cai, Zhen; Han, Fei; Xu, Chuan; Jin, Guoxiang; Sun, Li; Pan, Bo-Syong; Lai, Shiue-Wei; Hsu, Che-Chia; Xu, Jia; Chen, Zhong-Zhu; Li, Hong-Yu; Seth, Pankaj; Hu, Junbo; Zhang, Xuemin; Li, Huiyan; Lin, Hui-Kuan.
Afiliação
  • Zhang W; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China; Departmen
  • Wang G; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
  • Xu ZG; International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China.
  • Tu H; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China.
  • Hu F; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Dai J; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China.
  • Chang Y; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China.
  • Chen Y; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Lu Y; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Zeng H; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Cai Z; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Han F; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Xu C; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Jin G; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Sun L; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Pan BS; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Lai SW; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Hsu CC; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA.
  • Xu J; International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China.
  • Chen ZZ; International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China.
  • Li HY; University of Arkansas for Medical Sciences, College of Pharmacy, Division of Pharmaceutical Science, 200 South Cedar, Little Rock, AR 72202, USA.
  • Seth P; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Hu J; Department of Gastrointestinal Surgery Center and Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
  • Zhang X; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China.
  • Li H; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, National Center of Biomedical Analysis, Beijing, Beijing 100850, China.
  • Lin HK; Department of Cancer Biology, Wake Forest Baptist Medical Center, Wake Forest University, Winston Salem, NC 27101, USA; Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan. Electronic address: hulin@wakehealth.edu.
Cell ; 178(1): 176-189.e15, 2019 06 27.
Article em En | MEDLINE | ID: mdl-31155231
ABSTRACT
RLR-mediated type I IFN production plays a pivotal role in elevating host immunity for viral clearance and cancer immune surveillance. Here, we report that glycolysis, which is inactivated during RLR activation, serves as a barrier to impede type I IFN production upon RLR activation. RLR-triggered MAVS-RIG-I recognition hijacks hexokinase binding to MAVS, leading to the impairment of hexokinase mitochondria localization and activation. Lactate serves as a key metabolite responsible for glycolysis-mediated RLR signaling inhibition by directly binding to MAVS transmembrane (TM) domain and preventing MAVS aggregation. Notably, lactate restoration reverses increased IFN production caused by lactate deficiency. Using pharmacological and genetic approaches, we show that lactate reduction by lactate dehydrogenase A (LDHA) inactivation heightens type I IFN production to protect mice from viral infection. Our study establishes a critical role of glycolysis-derived lactate in limiting RLR signaling and identifies MAVS as a direct sensor of lactate, which functions to connect energy metabolism and innate immunity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Superfície Celular / Ácido Láctico / Proteínas Adaptadoras de Transdução de Sinal / Proteína DEAD-box 58 Limite: Animals / Female / Humans / Male Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Superfície Celular / Ácido Láctico / Proteínas Adaptadoras de Transdução de Sinal / Proteína DEAD-box 58 Limite: Animals / Female / Humans / Male Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article